Fig. 2 | Nature Communications

Fig. 2

From: Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers

Fig. 2

EZH2 is activated in neuroendocrine prostate cancer (NEPC). a Western blotting for EZH2 catalytic product H3K27me3 level and NE marker CHGA in LNCaP and 22Rv1 cells treated with either CSS or 10 μM MDV3100 for 72 h, without or with 5 nM DHT in the last 24 h. b Higher levels of H3K27me3 marks in NEPC NE1.3, NCI-H660, and 144-13 cells, as compared to LNCaP cells. H3K27me3 levels were also examined in patient-derived xenograft (PDX) NEPC MDA-PCA-144-13 tumor and adenocarcinoma MDA-PCA-133 tumor. Beta actin and total histone 3 (H3) were also examined as loading controls. c, d Downregulation of known EZH2 targets, SLIT2, DAB2IP, and ADRB2 in c NEPC NE1.3 and NCI-H660 cells as compared to LNCaP cells; and in d NEPC PDX tumor MDA-PCA-144-13 as compared to adenocarcinoma PDX tumor MDA-PCA-133. Y-axis shows relative fold changes in mRNA expression, normalized to GAPDH. Error bars in PCR results represent standard deviation (s.d.) of triplicate experiments

Back to article page